Results 61 to 70 of about 41,188 (289)
Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome
Clinical Medicine Insights: Case Reports, 2018 Hydroxyurea (HU) is a drug frequently used in the treatment of chronic myeloproliferative neoplasms. The most common side effects of this drug are pancytopenia, digestive and skin disorders.
Oriol Plans Galván +5 more
doaj +1 more source
Single-cell analysis based dissection of clonality in myelofibrosis
Nature Communications, 2020 Myelofibrosis is a myeloproliferative neoplasm. Here, the authors show the clonal evolution of myelofibrosis during JAK inhibitor therapy, revealing how the treatment results in an increase in clonal complexity and a gain of RAS pathway mutations.
Elena Mylonas +21 more
doaj +1 more source
Acute liver failure precipitated by acute Budd‐Chiari syndrome and complete portal vein thrombosis
Clinical Case Reports, 2021 Acute Budd‐Chiari syndrome and complete portal vein thrombosis are important features of myeloproliferative neoplasm that may occur simultaneously, resulting in acute liver failure.
Yuji Suzuki +3 more
doaj +1 more source
Leukemia Research Reports, 2023 We report a case of myeloid/lymphoid neoplasm with ZMYM2::FGFR1 rearrangement (MLNZMYM2::FGFR1) exhibiting a complex disease evolution. This neoplasm initially presented as T-lymphoblastic lymphoma (T-LBL) in lymph node and myeloproliferative neoplasm ...
Dong Chen +6 more
doaj +1 more source
Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms [PDF]
, 2015 Myeloproliferative neoplasms (MPN) are a diverse group of chronic hematological disorders that involve unregulated clonal proliferation of white blood cells.
Kapur, Reuben, Pandey, Ruchi
core +1 more source
772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination [PDF]
, 2021 Mathieu Gigoux +35 more
openalex +1 more source
Environmental and Molecular Mutagenesis, EarlyView.Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons +17 more
wiley +1 more source
Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
Hematology, Transfusion and Cell Therapy, 2018 Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
Maira da Costa Cacemiro +11 more
doaj +1 more source
Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study
JEADV Clinical Practice, EarlyView.ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary ...
David Croitoru +13 more
wiley +1 more source
Haematologica, 2017 High mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is negatively regulated by let-7 microRNA through binding to it’s 3′-untranslated region. Transgenic mice expressing Hmga2 with a truncation of its 3′-untranslated region
Chih-Cheng Chen +11 more
doaj +1 more source